Rj. Bielski et Rb. Lydiard, THERAPEUTIC TRIAL PARTICIPANTS - WHERE DO WE FIND THEM AND WHAT DOES IT COST, Psychopharmacology bulletin, 33(1), 1997, pp. 75-78
Billions of dollars are spent annually in the process of developing an
d marketing new therapeutic agents. While the methods for testing and
assuring safety of these newer agents receive intense scrutiny, the me
thods by which the patient samples for psychotropic agent studies are
recruited has received relatively little attention. It appears that sy
mptomatic volunteers who enter clinical psychopharmacology studies are
clinically comparable to treatment-seeking patient samples, There is
almost no information regarding the actual proportions of ''recruited'
' to treatment-seeking patients or how many symptomatic volunteers par
ticipate in more than one study, and the expense of advertising for sy
mptomatic volunteers has not been investigated. We surveyed 18 experie
nced investigators around the United States to identify: (1) the relat
ive proportion of clinical trial participants who are symptomatic volu
nteers versus treatment-seeking patients; (2) the proportion of study
volunteers who entered more than one clinical trial; and (3) the cost
of recruitment for investigators who conduct these studies. The findin
gs indicate that an average of 87.2 percent of subjects entering trial
s were recruited via advertising, Most participate in only one study.
The expense of identifying and recruiting appropriate symptomatic volu
nteers is significant, and appears to be increasing, Implications of t
hese findings will be discussed.